These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23095244)

  • 21. Modelling the adverse effects associated with ecstasy use.
    Fisk JE; Murphy PN; Montgomery C; Hadjiefthyvoulou F
    Addiction; 2011 Apr; 106(4):798-805. PubMed ID: 21182557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the acute subjective effects of MDMA/ecstasy.
    Baylen CA; Rosenberg H
    Addiction; 2006 Jul; 101(7):933-47. PubMed ID: 16771886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is emotional intelligence impaired in ecstasy-polydrug users?
    Craig L; Fisk JE; Montgomery C; Murphy PN; Wareing M
    J Psychopharmacol; 2010 Feb; 24(2):221-31. PubMed ID: 18801831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
    Verheyden SL; Maidment R; Curran HV
    J Psychopharmacol; 2003 Dec; 17(4):371-8. PubMed ID: 14870948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
    Parrott AC; Buchanan T; Scholey AB; Heffernan T; Ling J; Rodgers J
    Hum Psychopharmacol; 2002 Aug; 17(6):309-12. PubMed ID: 12404677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropsychiatric symptoms and past manganese exposure in a ferro-alloy plant.
    Bouchard M; Mergler D; Baldwin M; Panisset M; Roels HA
    Neurotoxicology; 2007 Mar; 28(2):290-7. PubMed ID: 16962176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
    Sumnall HR; Cole JC; Jerome L
    J Psychopharmacol; 2006 Sep; 20(5):670-82. PubMed ID: 16401654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Young adults' trajectories of Ecstasy use: a population based study.
    Smirnov A; Najman JM; Hayatbakhsh R; Plotnikova M; Wells H; Legosz M; Kemp R
    Addict Behav; 2013 Nov; 38(11):2667-74. PubMed ID: 23899430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users.
    Curran HV; Rees H; Hoare T; Hoshi R; Bond A
    Psychopharmacology (Berl); 2004 May; 173(3-4):425-33. PubMed ID: 14735288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self reported sleep quality and cognitive performance in ecstasy users.
    Montgomery C; Fisk JE; Wareing M; Murphy P
    Hum Psychopharmacol; 2007 Dec; 22(8):537-48. PubMed ID: 17960556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ecstasy on cooperative behaviour and perception of trustworthiness: a naturalistic study.
    Stewart LH; Ferguson B; Morgan CJ; Swaboda N; Jones L; Fenton R; Wall MB; Curran HV
    J Psychopharmacol; 2014 Nov; 28(11):1001-8. PubMed ID: 25122044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales.
    Bolanos SH; Khan DA; Hanczyc M; Bauer MS; Dhanani N; Brown ES
    Ann Allergy Asthma Immunol; 2004 May; 92(5):500-5. PubMed ID: 15191017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings.
    Hoshi R; Bisla J; Curran HV
    Drug Alcohol Depend; 2004 Dec; 76(3):297-304. PubMed ID: 15561480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change in frequency of acute and subacute effects of ecstasy in a group of novice users after 6 months of regular use.
    Raznahan M; Hassanzadeh E; Houshmand A; Kashani L; Tabrizi M; Akhondzadeh S
    Psychiatr Danub; 2013 Jun; 25(2):175-8. PubMed ID: 23793283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.
    Verheyden SL; Henry JA; Curran HV
    Hum Psychopharmacol; 2003 Oct; 18(7):507-17. PubMed ID: 14533132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study.
    Rodgers J; Buchanan T; Pearson C; Parrott AC; Ling J; Hefferman TM; Scholey AB
    J Psychopharmacol; 2006 May; 20(3):437-46. PubMed ID: 16174668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K; Parrott A; Turner J
    J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users.
    Parrott AC; Rodgers J; Buchanan T; Ling J; Heffernan T; Scholey AB
    Hum Psychopharmacol; 2006 Jul; 21(5):285-98. PubMed ID: 16856221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.